Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Touts New Product Strength In 2012 Year-End Call

This article was originally published in The Pink Sheet Daily

Executive Summary

The global pharmaceutical giant has had several new products hit the market in the last two years that have allowed it to retain a global leadership position despite tough economic circumstances and issues with its consumer segment.

You may also be interested in...

J&J Revitalizes Consumer Biz; Thrives On Pharma Strength In First Quarter

The healthcare conglomerate reported strong sales in the first quarter that were largely due to growth of its pharmaceutical business, but got an extra boost from the continued renewal of its consumer products portfolio.

FDA Approves Zytiga In Earlier Prostate Cancer Setting

FDA approval of Zytiga in the pre-chemo setting gives the androgen blocker a second prostate cancer indication and another revenue stream – but a short remaining patent life and a significant competitive threat may mitigate the achievement.

J&J’s New Path Forward – An Interview With Alex Gorsky

In a conversation shortly before taking the helm at Johnson & Johnson, CEO Gorsky discusses deal strategies, emerging markets, his experience on both the device and pharma sides of the business, and opportunities for drug/device convergence.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts